{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:16:33Z","timestamp":1794107793112,"version":"4.8.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jaci.2024.12.1066","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T12:11:49Z","timestamp":1734091909000},"page":"688-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Chimeric antigen receptor\u2013modified T-cell therapy: Recent updates and challenges in autoimmune diseases"],"prefix":"10.1016","volume":"155","author":[{"given":"Blandine","family":"Ca\u00ebl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"B\u00f4le-Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Garnache Ottou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.12.1066_bib1","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.12.1066_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3484","article-title":"Application of CAR-T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment","volume":"25","author":"Adabi","year":"2023","journal-title":"J Gene Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41591-023-02716-7","article-title":"Autoimmune disease is the next frontier for CAR T cell therapy","volume":"30","author":"Arnold","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2024.12.1066_bib6","doi-asserted-by":"crossref","first-page":"702","DOI":"10.15252\/emmm.201505869","article-title":"Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer","volume":"8","author":"Jin","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.865424","article-title":"Review: sustainable clinical development of CAR-T cells\u2014switching from viral transduction towards CRISPR-Cas gene editing","volume":"13","author":"Wagner","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jaci.2024.12.1066_bib9","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.2023020973","article-title":"Integration of \u03b6-deficient CARs into the CD3\u03b6 gene conveys potent cytotoxicity in T and NK cells","volume":"143","author":"Kath","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.12.1066_bib10","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","article-title":"CAR-T efficacy: is conditioning the key?","volume":"133","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.12.1066_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115688","article-title":"CAR-T cell therapy: from the shop to cancer therapy","volume":"24","author":"Uscanga-Palomeque","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2024.12.1066_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaci.2024.12.1066_bib13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2024.12.1066_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2024.12.1066_bib15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2024.12.1066_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s42255-022-00537-5","article-title":"CAR-based therapies: opportunities for immuno-medicine beyond cancer","volume":"4","author":"Aghajanian","year":"2022","journal-title":"Nat Metab"},{"key":"10.1016\/j.jaci.2024.12.1066_bib18","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.12.1066_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/imed.1039","article-title":"The breakthrough and the future: CD20 chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"2","author":"Tan Su Yin","year":"2022","journal-title":"ImmunoMedicine"},{"key":"10.1016\/j.jaci.2024.12.1066_bib20","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib21","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib23","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.12.1066_bib24","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2024.12.1066_bib25","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure\u00a0of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2024.12.1066_bib26","doi-asserted-by":"crossref","first-page":"10335","DOI":"10.1182\/blood-2022-169265","article-title":"Safety and efficacy of CD19 CAR-T cells for refractory systemic sclerosis: a phase I clinical trial","volume":"140","author":"Feng","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.12.1066_bib27","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2024.12.1066_bib28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19.CAR-T cell\u2013containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2024.12.1066_bib29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury","volume":"83","author":"Lodka","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2024.12.1066_bib30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib32","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib33","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.jaci.2024.12.1066_bib34","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.jaci.2024.12.1066_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jaci.2024.12.1066_bib36","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2024.12.1066_bib37","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/medicina57101080","article-title":"An updated review of pemphigus diseases","volume":"57","author":"Malik","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.jaci.2024.12.1066_bib38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In\u00a0vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2024.12.1066_bib39","doi-asserted-by":"crossref","first-page":"28950","DOI":"10.1073\/pnas.2012495117","article-title":"A biomimetic five-module chimeric antigen receptor (5MCAR) designed to target and eliminate antigen-specific T cells","volume":"117","author":"Kobayashi","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2024.12.1066_bib40","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2016.12.007","article-title":"Adoptive transfer of mRNA-transfected T cells redirected against diabetogenic CD8 T cells can prevent diabetes","volume":"25","author":"Fishman","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2024.12.1066_bib41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4049\/jimmunol.2100643","article-title":"CD8+ T cells expressing an HLA-DR1 chimeric antigen receptor target autoimmune CD4+ T cells in an antigen-specific manner and inhibit the development of autoimmune arthritis","volume":"208","author":"Whittington","year":"2022","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib42","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jaci.2024.12.1066_bib43","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen\u2013specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2024.12.1066_bib44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.jaci.2024.12.1066_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaci.2024.12.1066_bib46","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2024.12.1066_bib47","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib48","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR Treg cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib49","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3899\/jrheum.2022-0827","article-title":"Type I interferons in autoimmunity: implications in clinical phenotypes and treatment response","volume":"50","author":"Londe","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nrrheum.2009.237","article-title":"Type I interferons: crucial participants in disease amplification in autoimmunity","volume":"6","author":"Hall","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib52","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti\u2013interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2024.12.1066_bib53","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nri3865","article-title":"The multifaceted biology of plasmacytoid dendritic cells","volume":"15","author":"Swiecki","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.immuni.2018.12.027","article-title":"Plasmacytoid dendritic cells: development, regulation, and function","volume":"50","author":"Reizis","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2024.12.1066_bib55","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nm1590","article-title":"TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity","volume":"13","author":"Baccala","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib56","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib57","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2024.12.1066_bib58","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/bjd\/ljad105","article-title":"Production of functional plasmacytoid dendritic cells\u2013targeted CAR-T cells from patients with immune-mediated inflammatory diseases","volume":"189","author":"Ca\u00ebl","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib59","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaci.2024.12.1066_bib60","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2024.12.1066_bib61","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in\u00a0vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jaci.2024.12.1066_bib62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/annrheumdis-2019-eular.3028","article-title":"Op0224 Results of a phase 2 study of Rg6125, an anti\u2013cadherin-11 monoclonal antibody, in rheumatoid arthritis patients with an inadequate response to anti-TNFalpha therapy","volume":"78","author":"Finch","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2024.12.1066_bib63","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/bloodadvances.2022009117","article-title":"Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaci.2024.12.1066_bib64","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.12.1066_bib65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaci.2024.12.1066_bib66","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaci.2024.12.1066_bib67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bmt.2023.01.002","article-title":"Improved efficacy with early tocilizumab in the prophylaxis and treatment of cytokine release syndrome of chimeric antigen receptor T cell (CAR-T) therapy for diffuse large B-cell lymphoma than acute lymphoblastic leukemia","volume":"3","author":"Luan","year":"2023","journal-title":"Biomed Technol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis","volume":"33","author":"Grigor","year":"2019","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jaci.2024.12.1066_bib69","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.12.1066_bib70","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.jaci.2024.12.1066_bib71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib72","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib73","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/2159-8290.CD-NB2023-0091","article-title":"FDA investigating CAR-related T-cell malignancies","volume":"14","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaci.2024.12.1066_bib75","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib76","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.12.1066_bib77","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib78","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/jama.2023.27885","article-title":"T-cell lymphoma from CAR T-cell therapy\u2014a new safety notice","volume":"331","author":"Prasad","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2024.12.1066_bib79","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib80","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/antib12020030","article-title":"CCR6 as a potential target for therapeutic antibodies for the treatment of inflammatory diseases","volume":"12","author":"G\u00f3mez-Melero","year":"2023","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.jaci.2024.12.1066_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib82","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.12.1066_bib83","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib84","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.12.1066_bib85","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2024.12.1066_bib86","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.12.1066_bib87","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib88","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib89","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40364-022-00434-9","article-title":"Strategies to enhance CAR-T persistence","volume":"10","author":"Liu","year":"2022","journal-title":"Biomark Res"},{"key":"10.1016\/j.jaci.2024.12.1066_bib90","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor\u2013positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.12.1066_bib91","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1172\/JCI81217","article-title":"Memory T cell\u2013driven differentiation of naive cells impairs adoptive immunotherapy","volume":"126","author":"Klebanoff","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2024.12.1066_bib92","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2024.12.1066_bib93","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib94","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 enhances CAR-T-cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaci.2024.12.1066_bib95","doi-asserted-by":"crossref","first-page":"13125","DOI":"10.18632\/oncotarget.24442","article-title":"IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation\u2013dependent manner","volume":"9","author":"Loschinski","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaci.2024.12.1066_bib96","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2024.12.1066_bib97","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","article-title":"Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaci.2024.12.1066_bib98","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41467-022-35583-w","article-title":"Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy","volume":"14","author":"Trefny","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2024.12.1066_bib99","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.799380","article-title":"Immunosenescence and autoimmunity: exploiting the T-cell receptor repertoire to investigate the impact of aging on multiple sclerosis","volume":"12","author":"Amoriello","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib101","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood-2019-128068","article-title":"Upregulation of senescent\/exhausted phenotype of CAR T cells and induction of both Treg and myeloid suppressive cells correlate with reduced response to CAR\u00a0T cell therapy in relapsed\/refractory B cell malignancies","volume":"134","author":"Beider","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.12.1066_bib102","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/blood-2019-126191","article-title":"Influence of CD27\u2212CD28\u2212 T-cells on the therapeutic outcome in adult patients with relapsed or refractory diffuse large B-cell lymphoma after CART-infusion","volume":"134","author":"Worel","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.12.1066_bib103","first-page":"830","article-title":"Targeting cellular senescence to increase CAR-T cell fitness","volume":"8","author":"Bankoti","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaci.2024.12.1066_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front Transplant"},{"key":"10.1016\/j.jaci.2024.12.1066_bib105","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma","volume":"7","author":"Potnis","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaci.2024.12.1066_bib106","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.3390\/cancers14133168","article-title":"Umbilical cord blood as a source of less differentiated T cells to produce CD123 CAR-T cells","volume":"14","author":"Ca\u00ebl","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaci.2024.12.1066_bib107","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u201cOff-the-shelf\u201d allogeneic\u00a0CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2024.12.1066_bib108","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib109","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2024.12.1066_bib110","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41467-022-29668-9","article-title":"Allogeneic TCR\u03b1\u03b2 deficient CAR T-cells targeting CD123 in acute myeloid leukemia","volume":"13","author":"Sugita","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2024.12.1066_bib111","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41584-023-00968-8","article-title":"Chimeric receptors broaden the therapeutic landscape for autoimmune disease","volume":"19","author":"Finkel","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib112","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2024.12.1066_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1267762","article-title":"Unlocking the potential of Tregs: innovations in CAR technology","volume":"10","author":"Requejo Cier","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jaci.2024.12.1066_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166038","article-title":"Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy","volume":"14","author":"Kilgour","year":"2023","journal-title":"Front Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924023546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924023546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T09:17:40Z","timestamp":1744708660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674924023546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":114,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0091674924023546"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.12.1066","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor\u2013modified T-cell therapy: Recent updates and challenges in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.12.1066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}